Krystal Biotech's VYJUVEK Sales Drive 41% Revenue Surge

TL;DR

**Krystal Biotech is crushing it with VYJUVEK sales, making it a strong buy as profitability soars and cash piles up.**

AI Summary

Krystal Biotech, Inc. reported robust financial performance for the three and nine months ended September 30, 2025, driven by strong VYJUVEK sales. Product revenue, net, increased to $97.8 million for the three months ended September 30, 2025, up from $83.8 million in the prior year, representing a 16.7% increase. For the nine-month period, net product revenue surged to $282.0 million, a significant rise from $199.4 million in 2024, marking a 41.4% growth. Net income for the three months ended September 30, 2025, was $79.365 million, a substantial increase from $27.180 million in the same period of 2024. The nine-month net income reached $153.431 million, compared to $43.680 million in 2024. Operating expenses decreased to $56.426 million for the three months ended September 30, 2025, from $61.369 million in 2024, primarily due to the absence of a $12.5 million litigation settlement expense incurred in the prior year. The company's cash and cash equivalents, along with short-term investments, totaled approximately $731.1 million as of September 30, 2025, which management believes is sufficient to fund operations for at least the next 12 months. Key risks include the continued successful commercialization of VYJUVEK and the development of its product pipeline.

Why It Matters

This strong financial performance, particularly the significant revenue growth from VYJUVEK, signals Krystal Biotech's successful transition to a commercial-stage company. For investors, this demonstrates effective market penetration and potential for sustained profitability, especially with a cash position of $731.1 million. Employees benefit from the company's stability and growth, potentially leading to increased investment in R&D and expansion. Customers, particularly those relying on VYJUVEK, can expect continued product availability and support. In the competitive biotechnology landscape, Krystal Biotech's ability to generate substantial revenue from its approved gene therapy positions it as a formidable player, potentially attracting further partnerships and talent.

Risk Assessment

Risk Level: low — The company reported a net income of $153.431 million for the nine months ended September 30, 2025, a significant improvement from an accumulated deficit of $180.668 million as of December 31, 2024, now reduced to $27.237 million. With cash, cash equivalents, and short-term investments totaling $731.1 million, Krystal Biotech has ample liquidity to fund operations for at least the next 12 months, mitigating immediate financial risk.

Analyst Insight

Investors should consider increasing their position in KRYS, given the strong commercialization success of VYJUVEK and the significant increase in net income. The company's robust cash position of $731.1 million provides a solid foundation for future growth and pipeline development, suggesting continued upward momentum.

Financial Highlights

debt To Equity

0.09

revenue

$97.8M

operating Margin

42.3%

total Assets

$1.24B

total Debt

$102.2M

net Income

$79.365M

eps

$2.66

gross Margin

95.6%

cash Position

$731.1M

revenue Growth

+16.7%

Revenue Breakdown

Key Numbers

• $97.8M — Product revenue, net (Q3 2025) (Increased from $83.8M in Q3 2024, a 16.7% increase)
• $282.0M — Product revenue, net (9 months ended Sep 30, 2025) (Increased from $199.4M in 2024, a 41.4% increase)
• $79.365M — Net income (Q3 2025) (Increased from $27.180M in Q3 2024)
• $153.431M — Net income (9 months ended Sep 30, 2025) (Increased from $43.680M in 2024)
• $731.1M — Cash, cash equivalents, and short-term investments (As of September 30, 2025, sufficient for at least 12 months of operations)
• $27.2M — Accumulated deficit (As of September 30, 2025, significantly reduced from $180.668M at Dec 31, 2024)
• $56.426M — Total operating expenses (Q3 2025) (Decreased from $61.369M in Q3 2024)
• $12.5M — Litigation settlement expense (Incurred in Q3 2024, not present in Q3 2025)

Key Players & Entities

• Krystal Biotech, Inc. (company) — registrant
• VYJUVEK (company) — FDA, EC, and MHLW approved product
• U.S. Food and Drug Administration (regulator) — approving body for VYJUVEK
• European Commission (regulator) — approving body for VYJUVEK
• Japan's Ministry of Health, Labour, and Welfare (regulator) — approving body for VYJUVEK
• Jeune Aesthetics, Inc. (company) — wholly-owned subsidiary
• Delaware (company) — state of incorporation for Krystal Biotech and Jeune Aesthetics
• Nasdaq Global Select Market (company) — exchange where KRYS common stock is registered

FAQ

Risk Factors

• Commercialization of VYJUVEK [high — market]: The company's financial performance is heavily reliant on the continued successful commercialization of its lead product, VYJUVEK. Any challenges in market adoption, competition, or reimbursement could significantly impact revenue and profitability.
• Product Pipeline Development [high — operational]: Krystal Biotech's future growth depends on the successful development and regulatory approval of its product pipeline. Delays or failures in clinical trials or regulatory submissions for other pipeline candidates pose a significant risk.
• Regulatory Approvals and Compliance [medium — regulatory]: The biotechnology industry is subject to stringent regulatory oversight. Failure to obtain or maintain regulatory approvals for current or future products, or non-compliance with regulations, could halt product sales and development.
• Cash Burn and Funding Needs [medium — financial]: While the company has a strong cash position of $731.1 million as of September 30, 2025, ongoing research, development, and commercialization activities require substantial capital. Future funding needs could arise if development timelines extend or commercial success is slower than anticipated.
• Litigation and Legal Contingencies [low — legal]: The company has experienced litigation expenses in the past, such as the $12.5 million settlement in Q3 2024. Future legal disputes or unfavorable outcomes could result in significant financial costs and operational disruptions.

Industry Context

Krystal Biotech operates in the highly competitive and innovative biotechnology sector, focusing on gene therapies for rare diseases. The industry is characterized by significant R&D investment, long development cycles, and stringent regulatory hurdles. Success hinges on scientific breakthroughs, effective clinical trials, and successful commercialization strategies in niche markets.

Regulatory Implications

As a biotechnology company, Krystal Biotech is subject to rigorous oversight by regulatory bodies like the FDA. Successful commercialization of VYJUVEK and future pipeline products depends on maintaining compliance with manufacturing standards, post-market surveillance, and evolving regulatory guidelines. Any adverse regulatory actions could severely impact market access and revenue.

What Investors Should Do

1. Monitor VYJUVEK sales trajectory and market penetration.
2. Evaluate progress on the product pipeline.
3. Assess the impact of operating expense management.
4. Review cash burn rate and future funding requirements.

Key Dates

• 2025-09-30: End of Q3 2025 — Reported strong product revenue of $97.8M and net income of $79.365M, demonstrating continued commercial success of VYJUVEK.
• 2025-09-30: Balance Sheet Date — Company held $731.1 million in cash, cash equivalents, and short-term investments, sufficient for at least 12 months of operations.
• 2024-09-30: End of Q3 2024 — Reported product revenue of $83.8M and net income of $27.180M. This period included a $12.5M litigation settlement expense.
• 2024-12-31: End of Fiscal Year 2024 — Reported an accumulated deficit of $180.668M.
• 2025-09-30: End of Q3 2025 — Accumulated deficit reduced to $27.2M, reflecting significant profitability improvements.

Glossary

Product revenue, net

The total revenue generated from the sale of the company's products after deducting any returns, allowances, and discounts. (Key indicator of commercial success and market demand for Krystal Biotech's therapies, particularly VYJUVEK.)

Accumulated deficit

The cumulative net losses of a company since its inception, offset by any net profits. A negative number indicates the company has historically incurred more losses than profits. (Shows the company's historical profitability. The significant reduction from $180.668M to $27.2M indicates a strong shift towards profitability.)

Operating expenses

Costs incurred in the normal course of running a business, excluding cost of goods sold. This includes R&D, SG&A, and other operational costs. (Understanding the trend in operating expenses is crucial for assessing operational efficiency and the impact of one-time charges like litigation settlements.)

Cash, cash equivalents, and short-term investments

Highly liquid assets that can be readily converted to cash. This represents the company's readily available funds. (Indicates the company's financial health and its ability to fund operations, research, and development without immediate need for external financing.)

Income tax benefit (expense)

The amount of income tax expense or benefit recognized for a period. A benefit reduces the company's tax liability. (Significant income tax benefits can substantially increase net income, as seen in Q3 2025 due to the company's profitability.)

Right-of-use assets

Assets representing the right to use a leased asset over the lease term, recognized under ASC 842 for leases. (Reflects the company's use of leased facilities or equipment, impacting the balance sheet and depreciation expenses.)

Year-Over-Year Comparison

Krystal Biotech has demonstrated significant financial improvement compared to the prior year. Product revenue has seen substantial growth, with a 16.7% increase in Q3 2025 and a 41.4% increase year-to-date, driven by VYJUVEK sales. Net income has surged dramatically, reflecting improved operational efficiency and revenue growth. Operating expenses decreased in Q3 2025 primarily due to the absence of a significant litigation settlement expense incurred in the prior year, contributing to a much stronger net income and a substantial reduction in the accumulated deficit. The company's cash position remains robust, providing ample runway for continued operations.

Filing Documents

• krys-20250930.htm (10-Q) — 1207KB
• a3q25krysex311.htm (EX-31.1) — 11KB
• a3q25krysex312.htm (EX-31.2) — 11KB
• a3q25krysex321.htm (EX-32.1) — 11KB
• 0001711279-25-000087.txt ( ) — 6285KB
• krys-20250930.xsd (EX-101.SCH) — 37KB
• krys-20250930_cal.xml (EX-101.CAL) — 67KB
• krys-20250930_def.xml (EX-101.DEF) — 160KB
• krys-20250930_lab.xml (EX-101.LAB) — 541KB
• krys-20250930_pre.xml (EX-101.PRE) — 352KB
• krys-20250930_htm.xml (XML) — 1026KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements Condensed Consolidated Balance Sheets as of September 30, 2025 (unaudited) and December 31, 2024 3 Condensed Consolidated Statements of Operations and Comprehensive Income for the Three and Nine Months Ended September 30, 2025 and 2024 (unaudited) 4 Condensed Consolidated Statements of Stockholders' Equity for the Three and Nine Months Ended September 30, 2025 and 2024 (unaudited) 5 Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 and 2024 (unaudited) 7 Notes to Condensed Consolidated Financial Statements (unaudited) 8 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 18 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 30 Item 4.

Controls and Procedures

Controls and Procedures 31

OTHER INFORMATION

PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 32 Item 1A.

Risk Factors

Risk Factors 32 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 33 Item 3. Defaults Upon Senior Securities 33 Item 4. Mine Safety Disclosures 33 Item 5. Other Information 33 Item 6. Exhibits 33

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS Krystal Biotech, Inc. Condensed Consolidated Balance Sheets (unaudited) (in thousands, except par value) September 30, 2025 December 31, 2024 Assets Current assets Cash and cash equivalents $ 392,604 $ 344,865 Short-term investments 338,465 252,652 Accounts receivable, net 129,633 104,746 Inventory 37,632 26,508 Prepaid taxes 10,103 1,617 Prepaid expenses and other current assets 17,213 11,657 Total current assets 925,650 742,045 Property and equipment, net 148,871 155,168 Long-term investments 133,113 152,114 Right-of-use assets 7,447 6,280 Deferred tax asset, net of valuation allowance 24,680 — Other non-current assets 333 231 Total assets $ 1,240,094 $ 1,055,838 Liabilities and Stockholders' Equity Current liabilities Accounts payable $ 2,097 $ 4,985 Current portion of lease liability 1,698 1,217 Accrued rebates 55,769 36,804 Accrued expenses and other current liabilities 31,704 58,989 Total current liabilities 91,268 101,995 Lease liability 7,813 6,044 Other long-term liabilities 3,137 1,419 Total liabilities 102,218 109,458 Commitments and contingencies (see note 7) Stockholders' equity Common stock; $ 0.00001 par value; 80,000 shares authorized as of September 30, 2025 and December 31, 2024; 28,984 and 28,794 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively. — — Additional paid-in capital 1,164,013 1,127,238 Accumulated other comprehensive gain (loss) 1,100 ( 190 ) Accumulated deficit ( 27,237 ) ( 180,668 ) Total stockholders' equity 1,137,876 946,380 Total liabilities and stockholders' equity $ 1,240,094 $ 1,055,838 The accompanying notes are an integral part of these condensed consolidated financial statements. 3 Krystal Biotech, Inc. Condensed Consolidated Statements of Operations and Comprehensive Income (unaudited) Three Months Ended September 30, Nine Months Ended September 30, (in thousands, except per share data) 2025

View Full Filing

View this 10-Q filing on SEC EDGAR